2023-08-01 2024-07-31 false No description of principal activity Capium Accounts Production 1.1 12712577 2023-08-01 2024-07-31 12712577 bus:FullAccounts 2023-08-01 2024-07-31 12712577 bus:Micro-entities 2023-08-01 2024-07-31 12712577 bus:AuditExempt-NoAccountantsReport 2023-08-01 2024-07-31 12712577 bus:SmallCompaniesRegimeForAccounts 2023-08-01 2024-07-31 12712577 bus:PrivateLimitedCompanyLtd 2023-08-01 2024-07-31 12712577 2023-08-01 2024-07-31 12712577 2024-07-31 12712577 bus:RegisteredOffice 2023-08-01 2024-07-31 12712577 core:WithinOneYear 2024-07-31 12712577 core:AfterOneYear 2024-07-31 12712577 1 2023-08-01 2024-07-31 12712577 bus:Director1 2023-08-01 2024-07-31 12712577 bus:Director1 2024-07-31 12712577 bus:Director1 2022-08-01 2023-07-31 12712577 2022-08-01 12712577 bus:LeadAgentIfApplicable 2023-08-01 2024-07-31 12712577 2022-08-01 2023-07-31 12712577 2023-07-31 12712577 core:WithinOneYear 2023-07-31 12712577 core:AfterOneYear 2023-07-31 12712577 bus:EntityAccountantsOrAuditors 2022-08-01 2023-07-31 12712577 core:CostValuation core:Non-currentFinancialInstruments 2024-07-31 12712577 core:CostValuation core:Non-currentFinancialInstruments 2023-07-31 12712577 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2024-07-31 12712577 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2024-07-31 12712577 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2024-07-31 12712577 core:Non-currentFinancialInstruments 2024-07-31 12712577 core:Non-currentFinancialInstruments 2023-07-31 iso4217:GBP xbrli:shares xbrli:pure
Registered Number: 12712577
England and Wales

 

 

 

BIOVANTIC PHARMA LIMITED



Unaudited Financial Statements
 


Period of accounts

Start date: 01 August 2023

End date: 31 July 2024
Director AnnirudhaKumar Vora
Registered Number 12712577
Registered Office KEMP HOUSE
160 CITY ROAD LONDON
EC1V 2NX
1
  2024   2023
    £ £   £ £
Current assets 613,608      524,327   
Creditors: amount falling due within one year (52,561)     (16,552)  
Net current assets   561,047      507,775 
Total assets less current liabilities   561,047      507,775 
Creditors: amount falling due after more than one year   (453,272)     (462,318)
Net assets   107,775      45,457 
 

         
Capital and reserves   107,775      45,457 
 
NOTES TO THE ACCOUNTS

General Information
BIOVANTIC PHARMA LIMITED is a private company, limited by shares, registered in England and Wales, registration number 12712577, registration address KEMP HOUSE, 160 CITY ROAD LONDON, EC1V 2NX.

The presentation currency is £ sterling.
1.

Accounting policies

Significant accounting policies
Statement of compliance
These financial statements have been prepared in compliance with FRS 105 – The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.
Basis of preparation
The financial statements have been prepared under the historical cost convention as modified by the revaluation of land and buildings and certain financial instruments measured at fair value in accordance with the accounting policies.
The financial statements are prepared in sterling which is the functional currency of the company.
2.

Average number of employees

Average number of employees during the year was 1 (2023 : 1).

3.

Related parties

During the year the company entered into the following transactions with related parties:
Amount due from/to related party Provision for doubtful debt from the related party
2024
£
 2023
£
 2024
£
 2023
£
Biovantic Pharma Medical device Limited292,290 292,290 
Accord Clinical supplies Limited133,001 133,001 

Creditors balance include amount payable to Biovantic Medical Device Limited where ANNIRUDH Vora holds directorship.
Creditors balance include amount payable to Accord Clinical Supplies Limited where ANNIRUDH Vora holds directorship.

For the year ended 31 July 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's Responsibilities:
The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476.

The director acknowledges their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

These accounts have been prepared in accordance with the micro-entity provisions and FRS 105, the Financial Reporting Standard applicable to the micro-entities regime. The accounts have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. The income statement has not been delivered to the Registrar of Companies.
The financial statements were approved by the director on 11 August 2025 and were signed by:


--------------------------------
AnnirudhaKumar Vora
Director
2